ULTRAGENYX PHARMACEUTICAL INC. Cost of Goods Sold (Deprecated 2018-01-31)
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Cost of Goods Sold (Deprecated 2018-01-31) of $225.00 thousand for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-08.
Discontinued › Expense Statement › Cost of Sales
us-gaap:CostOfGoodsSold · last filed 2018-05-08
- ULTRAGENYX PHARMACEUTICAL INC. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $225.00K.
- ULTRAGENYX PHARMACEUTICAL INC. cost of goods sold (deprecated 2018-01-31) for fiscal 2017 was $1.00K.
| Period end | Cost of Goods Sold (Deprecated 2018-01-31) 3 month | Cost of Goods Sold (Deprecated 2018-01-31) 12 month |
|---|---|---|
| 2018-03-31 | $225.00K 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $1.00K 10-K · filed 2018-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |